Literature DB >> 25234798

Costs and work limitation of patients with ankylosing spondylitis in China.

Liudan Tu1, Jayanti Chamling Rai, Shuangyan Cao, Zhiming Lin, Zaiying Hu, Jieruo Gu.   

Abstract

OBJECTIVES: To access the annual direct, indirect costs and work limitation of AS patients in Chinese population and explore the determinants of cost.
METHODS: A retrospective, cross-sectional study was performed in 257 patients with AS in China. The participants completed questionnaires about disease characteristics, quality of life and direct and indirect costs. Only the patients with paid-work completed the Work Limitation Questionnaire (WLQ), a 25-item questionnaire that accesses the impact of chronic health conditions on job performance and productivity. Functional impairment and disease activity were assessed using the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Bath Akylosing Spondylitis Disease Activity Index (BASDAI). Quality of life was measured by the Short Form-36.
RESULTS: Of the 257 patients who completed the questionnaires, the mean age was 28.5 (SD=0.5) with mean disease duration of 6.52 years (SD=0.44). The mean BASDAI and BASFI score was 3.28 and 1.3, respectively. Among the 257 patients, 21.8% are students, 64.2% have a paid job and 10.5% without a job because of AS. 165 participants finished the WLQ with a mean WLQ index of 0.19 which corresponds to a 17% decrease in productivity. The annual estimated costs of each patient was $2714.18 while the indirect cost accounted for 64.7%. The annual direct cost significantly correlated with disease activity.
CONCLUSIONS: Our research is the first to provide information about the burden of AS and the work status of AS patients in mainland China, which may help to establish the treatment strategy and a policy of support.

Entities:  

Mesh:

Year:  2014        PMID: 25234798

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  6 in total

Review 1.  Taiwan Rheumatology Association consensus recommendations for the management of axial spondyloarthritis.

Authors:  James Cheng-Chung Wei; Chin-Hsiu Liu; Jui-Cheng Tseng; Lin-Fen Hsieh; Chun-Hsiung Chen; Hsin-Hua Chen; Hung-An Chen; Ying-Chou Chen; Chung-Tei Chou; Hsien-Tzung Liao; Yi-Chun Lin; Shue-Fen Luo; Deng-Ho Yang; Kai-Jieh Yeo; Wen-Chan Tsai
Journal:  Int J Rheum Dis       Date:  2019-11-27       Impact factor: 2.454

2.  Cost of Illness, Quality of Life, and Work Outcomes in Active Ankylosing Spondylitis Patients Treated With Adalimumab in China.

Authors:  Liudan Tu; Ya Xie; Zetao Liao; Yutong Jiang; Qing Lv; Shuangyan Cao; Qiujing Wei; Jieruo Gu
Journal:  Front Public Health       Date:  2020-11-24

3.  Serum RANKL levels in Chinese patients with ankylosing spondylitis: a meta-analysis.

Authors:  Feifei Ni; Yanchao Zhang; Yi Peng; Xiaoxiao Peng; Jianjun Li
Journal:  J Orthop Surg Res       Date:  2021-10-18       Impact factor: 2.359

4.  Predictors of Health-Related Quality of Life in Patients with Ankylosing Spondylitis in Southwest China.

Authors:  Yuqing Song; Hong Chen
Journal:  Patient Prefer Adherence       Date:  2021-08-28       Impact factor: 2.711

5.  Etanercept/celecoxib on improving MRI inflammation of active ankylosing spondylitis: A multicenter, open-label, randomized clinical trial.

Authors:  Liudan Tu; Minjing Zhao; Xiaohong Wang; Qingcong Kong; Zena Chen; Qiujing Wei; Qiuxia Li; Qinghong Yu; Zhizhong Ye; Shuangyan Cao; Zhimin Lin; Zetao Liao; Qing Lv; Jun Qi; Ou Jin; Yunfeng Pan; Jieruo Gu
Journal:  Front Immunol       Date:  2022-08-26       Impact factor: 8.786

6.  Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial.

Authors:  Qiuxia Li; Li Li; Liqi Bi; Changhong Xiao; Zhiming Lin; Shuangyan Cao; Zetao Liao; Jieruo Gu
Journal:  Trials       Date:  2016-07-22       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.